Enveda Biosciences obtained FDA IND clearance and initiated a phase I trial of ENV‑6946, a first‑in‑class oral small molecule for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The program represents Enveda’s move from natural‑product discovery into clinical development. ENV‑6946’s characterization positions it as an oral alternative to biologics for intestinal inflammation; phase I will evaluate safety, tolerability and translational biomarkers. Early clinical readouts will determine partnerability and next‑stage design.